Press Release FeedGet the RSS feed
Menu

Business Wire

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance

Business Wire

Ad hoc announcement pursuant to Art. 53 LR

ZUG, Switzerland, October 22, 2026--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026.

  • Record net sales of 4.765 billion USD for the first nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix.

  • Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma's proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators.

  • Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD).

  • Strengthening Galderma's dermatology platform, with the previously announced agreement to acquire ZO® Skin Health, a leading brand in the fast-growing physician-dispensed skincare category. The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and other customary closing conditions.

  • Further evolution as a listed company, with Galderma's inclusion in the Swiss Market Index (SMI) and an upgraded credit rating.

  • Raising 2026 full-year net sales guidance to 22.5-23.5% growth year-on-year at constant currency (previously 19-21%), and confirming Core EBITDA margin2 of approximately 26% at constant currency.

"Our strong performance in the first nine months of 2026 underscores the sustained momentum across our business and the strength of our integrated dermatology strategy. Robust demand for our differentiated, premium portfolio continues to drive growth, while we advance innovation and take decisive steps to strengthen our long-term growth prospects, including our agreement to acquire ZO Skin Health. Building on this momentum and our confidence in the business, we are raising our full-year net sales guidance."

FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER

GALDERMA

Commercial performance

For the first nine months of 2026, Galderma achieved record net sales of 4,765 million USD, with year-on-year growth of 25.1% at constant currency. Through focused execution of its proven, growth-driven integrated dermatology strategy, Galderma continued to deliver double-digit net sales growth in most of its top 10 markets.

  1. AIDassault SystèmesDassault Systèmes and Vertiv Team to Accelerate AI Factory Design and DeploymentCompanies: VertivCollaboration combines Dassault Systèmes' 3DEXPERIENCE agentic platform and virtual twins, and Vertiv infrastructure expertise to validate NVIDIA DSX AI factories before construction begins Integrated system validation helps reduce field complexity and accelerate the path from design kickoff to productive AI capacity Coll
  2. FinanceAzelis: Q3 2026 Results: Organic Growth Momentum Continued in the Third QuarterANTWERP, Belgium, October 22, 2026--Regulatory News: Azelis (Brussels:AZE): Highlights Q3 2026 Revenue in the third quarter increased by 8.5% in constant currency compared to the prior year to EUR 1.1bn, driven by strong organic growth of 8.2% , supplemented by a 0.3% growth contribution from acquisiti
  3. IndustrialMitsubishi Electric CorporationMitsubishi Electric Develops New OT Security Solution for Industrial EquipmentCompanies: Mitsubishi ElectricStrengthens product security and enables site-wide visibility for safer and more secure OT environments TOKYO, October 22, 2026--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a new operational technology (OT) security solution for industrial equipment, leveraging
  4. FinanceArcus Biosciences, Inc.Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockCompanies: Jefferies Financial GroupHAYWARD, Calif., October 22, 2026--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,
  5. RetailOptionMetrics Exhibiting at Asia EQDAs APAC options volume increases and retail options trading intensifies overall, leading options data and analytics provider offers derivatives professionals insights on leveraging options data to assess alpha and risk NEW YORK, October 22, 2026--OptionMetrics , the leading historical options data and
  6. ValueAct CapitalValueAct Calls for an Extraordinary General Meeting of Takara Holdings to Strengthen the Board and Hold Incumbent Outside Directors Accountable for Failure to Supervise ManagementSees significant untapped potential in Takara Holdings that more focused strategy and management execution could unlock. Seeks to hold incumbent Outside Directors accountable for the long-term underperformance of the Company and the Board's persistent failure to effectively supervise management. Proposes the election of t